Nuvectis Pharma (NVCT) Cash from Financing Activities (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Cash from Financing Activities data on file, last reported at $7000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 99.95% year-over-year to $7000.0; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (down 39.4% YoY), and the FY2025 full-year result was $29.1 million, up 149.79% from the prior year.
• Cash from Financing Activities fell to $7000.0 in Q1 2026, from $166000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $15.5 million in Q1 2025 to a low of -$578000.0 in Q2 2022.
• A 5-year average of $4.9 million and a median of $1.5 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 2386.33% in 2023 and tumbled 99.95% in 2026, its largest moves.
• Tracing NVCT's Cash from Financing Activities over 5 years: stood at -$131000.0 in 2022, then surged by 800.0% to $917000.0 in 2023, then soared by 317.56% to $3.8 million in 2024, then slumped by 95.66% to $166000.0 in 2025, then plunged by 95.78% to $7000.0 in 2026.
• Business Quant data shows NVCT's Cash from Financing Activities at $7000.0 in Q1 2026, $166000.0 in Q4 2025, and $13.1 million in Q3 2025.